Alkermes plc ALKS

NAS: ALKS | ISIN: IE00B56GVS15   15/09/2025
26,52 USD (-1,67%)
(-1,67%)   15/09/2025

12 september 2025 · Alkermes Appoints Joshua Reed as Chief Financial Officer · Persbericht

11 september 2025 · Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program · Persbericht

8 september 2025 · Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 · Persbericht

25 augustus 2025 · Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 · Persbericht

29 juli 2025 · Alkermes plc Reports Second Quarter 2025 Financial Results · Persbericht

21 juli 2025 · Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 · Persbericht

15 juli 2025 · Alkermes to Report Second Quarter Financial Results on July 29, 2025 · Persbericht

2 juni 2025 · Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference · Persbericht

2 juni 2025 · Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences · Persbericht

29 mei 2025 · Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 · Persbericht

1 mei 2025 · Alkermes plc Reports First Quarter 2025 Financial Results · Persbericht

30 april 2025 · New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) · Persbericht

17 april 2025 · Alkermes to Report First Quarter Financial Results on May 1, 2025 · Persbericht

2 april 2025 · Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference · Persbericht

1 april 2025 · Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia · Persbericht

27 maart 2025 · New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder · Persbericht

13 september 2024 · Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program · Persbericht

28 augustus 2024 · Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

22 augustus 2024 · Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 · Persbericht

24 juli 2024 · Alkermes plc Reports Second Quarter 2024 Financial Results · Persbericht

Mijn selecties